Alumis disclosed that its TYK2 inhibitor envudeucitinib failed to meet efficacy goals in a mid-stage systemic lupus erythematosus (SLE) study, according to the company’s Phase IIb Lumus trial results. Investors focused on the overall population, where Alumis did not show the expected improvement, even as management pointed to a prespecified signal in an IFN gene signature–defined subgroup. The company said it plans to continue into Phase III development in IFNGS-high patients, arguing the subgroup response curves separated during the 48-week primary endpoint for response rate. Nonetheless, analysts described the overall trial result as disappointing and highlighted the risk that the subgroup strategy may not translate to a broader market. The setback further underscores how challenging SLE trial heterogeneity remains for pathway-targeted approaches, especially in precision-enrichment designs.